VivoSim Labs VIVS
NASDAQ VIVS
$0.29 +0.01 (+3.06%)
At close: Aug 21, 2026 · 4:00 PM EDT

VivoSim Labs (VIVS) Cash from Financing Activities (2010 - 2026)

VivoSim Labs (VIVS) posted quarterly Cash from Financing Activities of $2.9 million for Q1 2026, down 9.58% year-over-year from $3.2 million in Q1 2025, and up 2540.68% quarter-over-quarter from -$118000.0 in Q4 2025.

VivoSim Labs (VIVS) Cash from Financing Activities (2010 - 2026) Analysis & Trends

VivoSim Labs' Cash from Financing Activities history runs 16 years deep, the most recent figure standing at $2.9 million for Q1 2026.

  • In Q1 2026, Cash from Financing Activities fell 9.58% year-over-year to $2.9 million; the TTM figure through Mar 2026 stood at $4.4 million (down 49.76% YoY), while the FY2026 annual figure was $4.4 million, down 49.76% from the prior year.
  • Cash from Financing Activities for Q1 2026 stood at $2.9 million, up from -$118000.0 in the prior quarter.
  • The five-year high for Cash from Financing Activities was $6.2 million in Q2 2024, with the low at -$371000.0 in Q3 2024.
  • The 4-year median for Cash from Financing Activities is $1.2 million (2023), against an average of $1.6 million.
  • The sharpest annual moves came in 2024 and 2025: Cash from Financing Activities plunged 118.41% in 2024, then soared 1106.44% in 2025.
  • VivoSim Labs' Cash from Financing Activities stood at $1.2 million in 2023, then slumped by 118.41% to -$216000.0 in 2024, then soared by 45.37% to -$118000.0 in 2025, then jumped by 2540.68% to $2.9 million in 2026.
  • Business Quant data shows VIVS's Cash from Financing Activities at $2.9 million in Q1 2026, -$118000.0 in Q4 2025, and $1.7 million in Q2 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Financing Activities (Qtr)
1 Vertex Pharmaceuticals 139.13 Bn 131.28 Bn 2.84 Bn -426.70 Mn
2 Regeneron Pharmaceuticals 85.77 Bn 77.77 Bn 3.93 Bn -1.22 Bn
3 Argenx Se 64.64 Bn 59.46 Bn 1.37 Bn -
4 Moderna 58.29 Bn 53.16 Bn 52.00 Mn 14.00 Mn
5 BeOne Medicines 41.92 Bn 36.82 Bn 1.53 Bn -6.05 Mn
6 Alnylam Pharmaceuticals 31.58 Bn 28.28 Bn 992.69 Mn 36.24 Mn
7 BioNTech SE 28.12 Bn 9.73 Bn 668.28 Mn -16.65 Mn
8 Insmed 27.39 Bn 26.22 Bn 358.27 Mn 27.18 Mn
9 Royalty Pharma 27.27 Bn 26.43 Bn - -273.15 Mn
10 VivoSim Labs 1.49 Mn 1.49 Mn - -118,000.00

Historic Data

Download Data
DateValue
Jun 30, 2026 -118,000.00
Jun 30, 2026 -118,000.00
Mar 31, 2026 2.88 Mn
Mar 31, 2026 2.88 Mn
Dec 31, 2025 -118,000.00
Dec 31, 2025 -118,000.00
Jun 30, 2025 1.68 Mn
Jun 30, 2025 1.68 Mn
Mar 31, 2025 3.19 Mn
Mar 31, 2025 3.19 Mn
Dec 31, 2024 -216,000.00
Dec 31, 2024 -216,000.00
Sep 30, 2024 -371,000.00
Sep 30, 2024 -371,000.00
Jun 30, 2024 6.25 Mn
Jun 30, 2024 6.25 Mn
Mar 31, 2024 264,000.00
Mar 31, 2024 264,000.00
Dec 31, 2023 1.17 Mn
Dec 31, 2023 1.17 Mn